Novartis AG Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (59)

Latest Posts

About This Stock More About This Stock
E Statistics Lesson
Article By: Vivian Lewis
Sunday, July 29, 2018 10:20 AM EDT
I did graduate work on statistics and therefore know exactly what went wrong with some of the FAANG stocks. Blame The Law Of Large Numbers which applies to Netflix, Facebook, and now Twitter and Intel.
In this article: BP, NOK, NVS, VOD, ESALY, NPSNY, OROCF, TEVA, MNILY, AVLIF, AGC, EXG, JOF, PDI
Read
Week In Review Ending July 22: How Trump's Policies Moved Stocks
Article By: The Fly
Sunday, July 22, 2018 9:13 PM EDT
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap.
In this article: CAU, BA, F, GM, HMC, MRK, NVS, PFE, SNY, TM, DDAIF, NSANY, RHHBY, VLKAY, GOOG, GOOGL, FCAU
Read
E Market Harbingers Like Copper
Article By: Vivian Lewis
Sunday, July 22, 2018 10:19 AM EDT
Copper is supposedly a harbinger of economic health, rising in advance of economic growth and falling in advance of recessions. Copper is due for a recovery starting as soon as next month according to the London Metal Exchange.
In this article: DIS, EXG, NOK, NVS, DLUEY, MELI, AMZN, CMCSA, TEVA, FOXA, CCJ, SLB
Read
Biotechs Cruise Onto Green Screen: July Looks Good
Article By: Rod Raynovich
Thursday, July 19, 2018 12:16 PM EDT
Biotechs cruised through the choppy market of late June to rally with many mid-caps rolling up and major ETFs up creeping toward 2018 highs. However, with earnings reports coming up, we could expect some selling depending on top line growth.
In this article: FBT, MRK, NVS, ACAD, IBB, CELG, VRTX, XBI, NVCR, CRSP, AMGN, CTNI, JNJ
Read
Novartis Q2 Earnings Miss, Sales Top On Cosentyx, Entresto
Article By: Zacks Investment Research
Wednesday, July 18, 2018 11:00 PM EDT
Swiss pharma giant Novartis AG reported results for second-quarter 2018, wherein revenues beat estimate, driven by strong performance of Cosentyx and Entresto. However, earnings fell short.
In this article: NVS Also: GSK, ONCE, AMGN, ABBV
Read

PARTNER HEADLINES

Latest Tweets for $NVS

No tweets yet!

$NVS

OncoSec Raising Its Profile In Fight Against Cancer
BreakingBad News 9/6/2017 3:48:05 PM

More good news on the war against #Cancer, thanks. #Novartis also has made great progress against B-cell acute lymphoblastic leukemia: www.talkmarkets.com/.../finally-a-cure-for-cancer $ONCS $NVS

Finally… A Cure for Cancer?
BreakingBad News 9/6/2017 3:30:54 PM

Lot of good news against the war on #Cancer. Also just read this about #OncoSec: www.talkmarkets.com/.../oncosec-raising-its-profile-in-fight-against-cancer $ONCS $NVS

Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Terry Chrisomalis 5/1/2017 12:22:24 AM

Yes it does indeed. #Novartis has been doing very well lately. $NVS

Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Danielle Rogers 4/30/2017 5:29:49 PM

Triple the effectiveness over a placebo looks very promising! $NVS

1 to 5 of 5 comments